文献速递前列腺增生与排尿功能障碍

下尿路功能障碍研究网络症状指数-29问卷评估良性前列腺增生患者α受体阻滞剂治疗反应的效果:一项前瞻性多中心队列研究

Efficacy of Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 Questionnaire in Assessing Alpha-blocker Treatment Response in Patients With Benign Prostatic Hyperplasia: A Prospective, Multicenter, Cohort Study.
PubMed 文献 · Urology · 2024-11-15

本研究为前瞻性非随机多中心队列研究,纳入2023年1月至4月在泌尿外科门诊就诊的135例下尿路症状男性患者,在α受体阻滞剂治疗前及治疗1个月末完成IPSS与LURN SI-29问卷、尿流率及残余尿评估。平均IPSS由18.4降至11.2(P=.001),平均LURN SI-29评分由37.02降至22.4(P=.001),两者改善率分别为67.1%±54.3%与64.2%±34.1%,且相互相关(Pearson相关系数=0.79,R2=0.63,P=.001);平均Qmax由10.3升至11.9 ml/s(P=.001),不同α受体阻滞剂类型间无显著差异。作者认为LURN SI-29与IPSS强相关,可用于评估α受体阻滞剂疗效。

要点

  • 135例下尿路症状男性,α受体阻滞剂治疗1个月后平均IPSS由18.4降至11.2(P=.001)。
  • 平均LURN SI-29评分由37.02降至22.4(P=.001),与IPSS改善相关(Pearson相关系数=0.79)。
  • 平均Qmax由10.3升至11.9 ml/s(P=.001),不同α受体阻滞剂类型间无显著差异。

核心结论

  • 在开始α受体阻滞剂治疗的下尿路症状患者中,LURN SI-29与IPSS呈强相关。
  • LURN SI-29 may be employed for the purpose of evaluating the efficacy of alpha-blocker therapy(作者认为LURN SI-29可用于评估α受体阻滞剂治疗疗效)。

研究设计与样本

  • 前瞻性、非随机、多中心队列研究,纳入2023年1月至4月就诊于泌尿外科门诊的下尿路症状男性患者。
  • 在α受体阻滞剂治疗开始前及治疗第1个月末完成IPSS和LURN SI-29问卷、尿流率检查及残余尿评估。
  • 研究队列共135例患者。

主要发现

  • 平均IPSS由18.4降至11.2(P=.001)。
  • 平均LURN SI-29评分由37.02降至22.4(P=.001)。
  • IPSS与LURN SI-29评分的改善率分别为67.1%±54.3%与64.2%±34.1%,两者相关(Pearson相关系数=0.79,R2=0.63,P=.001)。
  • 平均Qmax由10.3升至11.9 ml/s(P=.001)。
  • 不同α受体阻滞剂类型间未发现显著差异。

临床怎么用

  • 作者认为LURN SI-29可用于评估α受体阻滞剂治疗疗效,并可能为了解尿失禁、排尿后症状和疼痛等领域提供信息。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of the symptoms of the Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire in assessing alpha-blocker treatment response in patients with lower urinary tract symptoms (LUTS). METHODS: This prospective, non-randomized, multicentre trial included males with LUTS who visited urology outpatient clinics between January and April 2023. The most employed LUTS questionnaire is the International Prostate Symptom Score (IPSS), while the LURN SI-29 was also utilized. Prospective monitoring comprised the completion of IPSS and LURN SI-29 forms, uroflowmetry, and residual urine assessment prior to the initiation of alpha-blocker therapy and at the conclusion of the first month of treatment. RESULTS: The study cohort comprised 135 patients. There was a significant enhancement in the mean IPSS, which decreased from 18.4 to 11.2 (P = .001). Furthermore, the mean LURN SI-29 score exhibited a significant decline, from 37.02 to 22.4 (P = .001). The improvement in IPSS and LURN SI-29 scores was 67.1% ± 54.3% and 64.2% ± 34.1%, respectively. Additionally, these improvements were found to be correlated (Pearson correlation coefficient = 0.79, R2 = 0.63, P = .001). The mean Qmax increased from 10.3 to 11.9 ml/s (P = .001). No significant difference was identified between alpha-blocker types. CONCLUSION: A strong correlation was observed between LURN SI-29 and IPSS among patients with LUTS who were initiated on alpha-blocker therapy. LURN-SI-29 may be employed for the purpose of evaluating the efficacy of alpha-blocker therapy and may additionally offer insight into the domains of incontinence, post-micturition symptoms, and pain.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Arikan O, Kazan O, Arikan MG, et al. Efficacy of Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 Questionnaire in Assessing Alpha-blocker Treatment Response in Patients With Benign Prostatic Hyperplasia: A Prospective, Multicenter, Cohort Study. Urology. 2024. PMID: 39551396. doi:10.1016/j.urology.2024.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。